Beyond Air, Inc. (XAIR)

NASDAQ: XAIR · IEX Real-Time Price · USD
2.040
-0.010 (-0.49%)
Feb 29, 2024, 3:59 PM EST - Market closed
-0.49%
Market Cap 73.88M
Revenue (ttm) 689,000
Net Income (ttm) -66.70M
Shares Out 36.04M
EPS (ttm) -2.13
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 277,843
Open 2.080
Previous Close 2.050
Day's Range 1.920 - 2.100
52-Week Range 1.170 - 7.160
Beta -0.23
Analysts Strong Buy
Price Target 11.25 (+451.47%)
Earnings Date Feb 12, 2024

About XAIR

Beyond Air, Inc. operates as a commercial-stage medical device and biopharmaceutical company in the United States. The company engages in the development of LungFit platform, a nitric oxide generator and delivery system. It offers LungFit PH for the treatment of persistent pulmonary hypertension of the newborn. The company is also developing LungFit PRO for the treatment of viral lung infections, such as community-acquired viral pneumonia, including COVID-19, as well as bronchiolitis in hospitalized patients; and LungFit GO for the treatment of... [Read more]

Industry Medical Devices
Sector Healthcare
CEO Steven Adam Lisi
Employees 98
Stock Exchange NASDAQ
Ticker Symbol XAIR
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 4 analysts, the average rating for XAIR stock is "Strong Buy." The 12-month stock price forecast is $11.25, which is an increase of 451.47% from the latest price.

Price Target
$11.25
(451.47% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Beyond Air® Reports Financial Results for Third Quarter of Fiscal Year 2024

Commercial demand for LungFit® PH increasing; manufacturing of upgraded devices is ramping up to meet growing demand

17 days ago - GlobeNewsWire

Beyond Air® Schedules Third Fiscal Quarter 2024 Financial Results Conference Call and Webcast

GARDEN CITY, N.Y., Jan. 18, 2024 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harness...

6 weeks ago - GlobeNewsWire

Beyond Cancer™ Phase 1 Study Clears Cohort 1 in Patients with Advanced Relapsed or Refractory Unresectable Primary or Metastatic Cutaneous or Subcutaneous Solid Tumors

No dose limiting toxicities were reported in the first cohort of ultra-high concentration of nitric oxide administered at 25,000 parts per million (PPM)

2 months ago - GlobeNewsWire

Beyond Air® To Participate in the 35th Annual Piper Sandler Healthcare Conference

GARDEN CITY, N.Y., Nov. 15, 2023 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”) a commercial stage medical device and biopharmaceutical company focused on harnessi...

3 months ago - GlobeNewsWire

Beyond Air® Reports Financial Results for Second Quarter of Fiscal Year 2024

Provides fiscal year 2025 revenue guidance of $12 - $16 million US pilot trial of LungFit® PRO to treat viral community acquired pneumonia (VCAP) underway with data expected mid-calendar 2024 Beyond C...

3 months ago - GlobeNewsWire

Beyond Cancer™ Presents Positive First-in-Human Clinical Data for Ultra-High Concentration Nitric Oxide (UNO) Therapy in Solid Tumors During the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting

First-in-human Phase 1 study demonstrates early clinical proof of concept Positive clinical biomarker data demonstrate evidence of immune system activation and the translation of the immunogenic respo...

4 months ago - GlobeNewsWire

Beyond Air® Schedules Second Fiscal Quarter 2024 Financial Results Conference Call and Webcast

GARDEN CITY, N.Y., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”) a commercial stage medical device and biopharmaceutical company focused on harnessi...

4 months ago - GlobeNewsWire

Beyond Air® To Participate in the Truist Securities BioPharma Symposium

GARDEN CITY, N.Y., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”) a commercial stage medical device and biopharmaceutical company focused on harnessi...

4 months ago - GlobeNewsWire

Beyond Cancer™ Publishes Pre-Clinical Data in Cells Demonstrating that the Combination of Ultra-High Concentration Nitric Oxide (UNO) and Anti-mPD-1 Therapy Improves Tumor Regression Rates and Survival in Mice

UNO therapy results in a more immunogenic tumor microenvironment (TME) as well as a systemic response that overcomes anti-PD-1 resistance

4 months ago - GlobeNewsWire

Beyond Cancer™ Presents Positive Preclinical Data for Ultra-High Concentration Nitric Oxide (UNO) in Combination with Checkpoint Inhibitor Therapy During the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

50,000 or 100,000 ppm UNO alone or in combination with anti-mCTLA-4 more than tripled antigen specific central memory T-cell response versus anti-mCTLA-4 alone

4 months ago - GlobeNewsWire

Beyond Air® Receives Innovative Technology Contract from Vizient for LungFit®PH

Contract awarded for products that bring improvement to health care industry Contract awarded for products that bring improvement to health care industry

4 months ago - GlobeNewsWire

Beyond Cancer™ Selected to Present Proffered Posters Discussing Data from the UNO Therapy Program at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

GARDEN CITY, N.Y. and HAMILTON, Bermuda, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Beyond Cancer, Ltd., an affiliate of Beyond Air, Inc. (NASDAQ: XAIR) that is developing ultra-high concentration nitric oxide...

5 months ago - GlobeNewsWire

Beyond Air® To Participate in the Roth MKM 2023 Healthcare Opportunities Conference

GARDEN CITY, N.Y., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”) a commercial stage medical device and biopharmaceutical company focused on harnessi...

5 months ago - GlobeNewsWire

Beyond Cancer™ to Present Initial Clinical Data for Ultra-High Concentration Nitric Oxide Therapy at the 2023 SITC Annual Meeting

Abstract titles to be presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting were released publicly today at 9:00 a.m. EDT Abstract titles to be presented at the Society for Immuno...

5 months ago - GlobeNewsWire

Beyond Air® Announces Publication of Positive New Preclinical Data for the Treatment of Autism Spectrum Disorder

New data demonstrates a therapeutic effect for at least 10 days after a single subcutaneously (SC) injection of an extended-release selective neuronal nitric oxide synthase (nNOS) inhibitor

5 months ago - GlobeNewsWire

Beyond Air® and Getz Healthcare Enter Strategic Collaboration to Commercialize LungFit PH in Asia-Pacific Region

Partnership provides access to hospitals in key Asia-Pacific countries Getz Healthcare will make a payment to Beyond Air upon receipt of CE Mark Beyond Air will receive royalty payments based on net s...

6 months ago - GlobeNewsWire

Beyond Air® To Participate in BTIG's 2023 Virtual Biotechnology Conference

GARDEN CITY, N.Y., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”) a commercial stage medical device and biopharmaceutical company focused on harnessi...

7 months ago - GlobeNewsWire

Top 5 Health Care Stocks Which Could Rescue Your Portfolio This Quarter

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Other symbols: BCLICOSMPTGXSHCR
7 months ago - Benzinga

Beyond Air® Schedules First Fiscal Quarter 2024 Financial Results Conference Call and Webcast

GARDEN CITY, N.Y., July 24, 2023 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”) a commercial stage medical device and biopharmaceutical company focused on harnessi...

7 months ago - GlobeNewsWire

Beyond Air® Reports Financial Results for Fourth Quarter and Fiscal Year-End 2023

Successfully completed phase 1 of U.S. commercial launch, with multiple hospitals contracted, and have initiated phase 2 of launch for LungFit® PH for the treatment of term and near-term neonates with...

9 months ago - GlobeNewsWire

Beyond Air® Secures up to $40 Million Debt Financing

Funding to support the commercialization of LungFit® PH and advance the clinical development of high concentration nitric oxide treatment using Beyond Air's revolutionary LungFit platform technology F...

9 months ago - GlobeNewsWire

Beyond Air® Schedules Fiscal Year End 2023 Financial Results Conference Call and Webcast

GARDEN CITY, N.Y., May 16, 2023 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a commercial stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for...

10 months ago - GlobeNewsWire

Beyond Cancer™ Presents Positive Preclinical Data for Ultra-High Concentration Nitric Oxide (UNO) Therapy in Solid Tumors During the American Association for Cancer Research (AACR) 2023 Annual Meeting

Single and repeat dosing of UNO improves outcomes compared to checkpoint inhibitor monotherapy in the aggressive 4T1 breast cancer model

11 months ago - GlobeNewsWire

5 Stocks Insiders Have Built Positions in Over the Past 3 Months

According to the Insider Cluster Buys Screen, a Premium feature of GuruFocus, five stocks that have high number of unique insider buys over the past three months are Air Transport Services Group Inc. ...

Other symbols: ATSGNEWTSCHWVLY
11 months ago - GuruFocus

Beyond Air® Appoints Jeff Myers, M.D. Ph.D. as Chief Medical Officer

Dr. Myers brings extensive executive experience leading the development of clinical programs through US and global regulatory approval Dr. Myers brings extensive executive experience leading the devel...

1 year ago - GlobeNewsWire